337 related articles for article (PubMed ID: 32169477)
21. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
23. High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
Baldacci S; Figeac M; Antoine M; Descarpentries C; Kherrouche Z; Jamme P; Copin MC; Tulasne D; Nanni I; Beau-Faller M; Melaabi S; Levallet G; Quoix E; Moro-Sibilot D; Friard S; Missy P; Barlesi F; Cadranel J; Cortot AB
J Thorac Oncol; 2020 Jan; 15(1):120-124. PubMed ID: 31605799
[TBL] [Abstract][Full Text] [Related]
24. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
[TBL] [Abstract][Full Text] [Related]
25. Lung Cancer with
Fujino T; Suda K; Mitsudomi T
Lung Cancer (Auckl); 2021; 12():35-50. PubMed ID: 34295201
[No Abstract] [Full Text] [Related]
26. Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With
Lau SCM; Perdrizet K; Fung AS; Mata DGMM; Weiss J; Holzapfel N; Liu G; Bradbury PA; Shepherd FA; Sacher AG; Feilotter H; Sheffield B; Hwang D; Tsao MS; Cheng S; Cheema P; Leighl NB
JTO Clin Res Rep; 2023 Oct; 4(10):100562. PubMed ID: 37744308
[TBL] [Abstract][Full Text] [Related]
27. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
28. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
29. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy.
Fang W; Huang Y; Gu W; Gan J; Wang W; Zhang S; Wang K; Zhan J; Yang Y; Huang Y; Zhao H; Zhang L
Transl Lung Cancer Res; 2020 Aug; 9(4):1258-1267. PubMed ID: 32953503
[TBL] [Abstract][Full Text] [Related]
30. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
31. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
[No Abstract] [Full Text] [Related]
32. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
33. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
34. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Bylicki O; Paleiron N; Assié JB; Chouaïd C
Onco Targets Ther; 2020; 13():5691-5706. PubMed ID: 32606781
[TBL] [Abstract][Full Text] [Related]
35. Acquired
Li A; Yang JJ; Zhang XC; Zhang Z; Su J; Gou LY; Bai Y; Zhou Q; Yang Z; Han-Zhang H; Zhong WZ; Chuai S; Zhang Q; Xie Z; Gao H; Chen H; Wang Z; Wang Z; Yang XN; Wang BC; Gan B; Chen ZH; Jiang BY; Wu SP; Liu SY; Xu CR; Wu YL
Clin Cancer Res; 2017 Aug; 23(16):4929-4937. PubMed ID: 28396313
[No Abstract] [Full Text] [Related]
36. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
[TBL] [Abstract][Full Text] [Related]
37. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
Deng HY; Qiu XM; Zhu DX; Tang XJ; Zhou Q
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4623-4628. PubMed ID: 36171456
[TBL] [Abstract][Full Text] [Related]
38. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
Lai GGY; Guo R; Drilon A; Shao Weng Tan D
Cancer Treat Rev; 2022 Nov; 110():102444. PubMed ID: 36108503
[TBL] [Abstract][Full Text] [Related]
39. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
[TBL] [Abstract][Full Text] [Related]
40. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]